End-of-day quote
Other stock markets
|
||
- USD | - |
Apr. 30 | North American Morning Briefing : More Earnings -2- | DJ |
Apr. 29 | Altimmune Shares Decline After Guggenheim Downgrade | MT |
Financials (USD)
Sales 2024 * | 35.71M | Sales 2025 * | 28.57M | Capitalization | 518M |
---|---|---|---|---|---|
Net income 2024 * | -59M | Net income 2025 * | -158M | EV / Sales 2024 * | 11.9 x |
Net cash position 2024 * | 91.94M | Net cash position 2025 * | 285M | EV / Sales 2025 * | 8.15 x |
P/E ratio 2024 * |
-7.74
x | P/E ratio 2025 * |
-4.81
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.22% |
Latest transcript on Altimmune Inc
Managers | Title | Age | Since |
---|---|---|---|
Vipin K. Garg
CEO | Chief Executive Officer | 67 | 18-11-29 |
Director of Finance/CFO | 66 | 21-12-30 | |
Anthony Blandin
CMP | Compliance Officer | - | 22-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mitchel Sayare
CHM | Chairman | 76 | 10-03-31 |
Mack Gill
BRD | Director/Board Member | 72 | 04-07-31 |
Philip Hodges
BRD | Director/Board Member | 56 | 03-08-31 |
1st Jan change | Capi. | |
---|---|---|
+8.96% | 105B | |
-1.43% | 104B | |
+5.24% | 22.94B | |
-12.15% | 22.34B | |
-6.31% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+38.61% | 12.63B | |
+313.59% | 8.49B |